---
title: "LRP5"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "# Gene Information for LRP5"
tags: ['LRP5', 'BoneDisorders', 'WntSignalingPathway', 'Mutation', 'Osteoporosis', 'BisphosphonateTherapy', 'DrugResponse', 'HighBoneMassSyndrome']
---

# Gene Information for LRP5

## Gene Position and Pathology

LRP5, or Low-Density Lipoprotein Receptor-Related Protein 5, is a protein-coding gene located on chromosome 11 at position 11q13.2. Mutations in the LRP5 gene are associated with various bone disorders, including osteoporosis-pseudoglioma syndrome, high bone mass syndrome, and osteoporosis.

## Gene Function 

LRP5 plays a crucial role in the Wnt signaling pathway, which modulates bone mass through the regulation of osteoblast and osteoclast activity. It is involved in the formation and maintenance of bones by regulating bone formation and resorption processes.

## External IDs and Aliases

- HGNC: 6704
- NCBI Entrez: 4041
- Ensembl: ENSG00000164305
- OMIM: 603506
- UniProtKB/Swiss-Prot: O40425

Aliases:
- BMND1
- EVR1
- HBM
- LR3
- OPS
- OPTA1
- OWSDP
- VBCH

## AA Mutation List and Mutation Type with dbSNP ID

The following is a list of amino acid (AA) mutations for LRP5 gene along with the mutation type and their dbSNP IDs:

| AA Mutation   | Mutation Type | dbSNP IDs |
| ------------- | -------------| ----------|
| R531Q | Missense | rs118203069 |
| R1170W | Missense | rs121908241 |
| A214V | Missense | rs121908235 |
| G171V | Missense | rs121908236 |
| G715D| Missense | rs121908241 |
| R1033Q | Missense | rs121908238 |

## Somatic SNVs/InDels with dbSNP ID

The following is a list of somatic SNVs/InDels with their respective dbSNP IDs in the LRP5 gene:

| SNV/InDel  | dbSNP IDs |
| ---------- | --------- |
| rs750012020| rs750012020 |
| rs587776778| rs587776778|

## Related Disease

Mutations in the LRP5 gene are associated with the following conditions:

- Osteoporosis-pseudoglioma syndrome (OPPG)
- High bone mass syndrome (HBMS)
- Osteoporosis (OP)

## Treatment and Prognosis

There is currently no cure for LRP5-related disorders. However, treatment may involve bisphosphonate therapy and management of symptoms such as fractures and bone deformities. The prognosis for LRP5-related disorders varies, depending on the severity of the symptoms and the age at diagnosis.

## Drug Response

Studies have suggested that the LRP5 gene may play a role in drug response to certain medications, such as bisphosphonates and selective estrogen receptor modulators (SERMs).

## Related Papers

1. From Subject: "LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders", by Boyden et al., published in Nature on March 30, 2002. DOI: 10.1038/nature01025

2. From Subject: "LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased LRP5 function in vitro", by Gong et al., published in Journal of Bone and Mineral Research on September 10, 2004. DOI: 10.1359/JBMR.040914

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**